Now Available: Netherlands Pharmaceuticals & Healthcare Report Q1 2014
As a result of the high and increasing average age in the Netherlands, our outlook for healthcare expenditure in the country is broadly positive. On the other hand, we maintain that the pharmaceutical sector in the Netherlands will not see a return to positive growth until 2016. Despite expectations for a return to positive economic growth in 2014, the government will persist with austerity measures to comply with the EU's budget criteria. We therefore maintain that further restrictions on medicines...
View full press release